Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
STRONG BUY
They have 5 Drugs approved and another 5 Drugs awaiting FDA approval i dont know what you talking about there are Biotechs who are longer than a decade on the stock market who produced nothing to date not even a generic drug .And IPCi is not the first company that get a drug rejected by FDA at the first time even Giants like Teva and Pfizer had problems to get their abuse deterrent drugs approved at the first time .
looks like some Institutional investors selling out who are not allowed to hold penny stocks once its over then stock will likely go back above $1 .
IPCI006 is NOT a new drug so the NDA filing could happen in next 12-18 months
at around $9 million valuation which is below their cash balance its a pure gift especially their podras platform is great and add all the products in their pipeline . This company is more than a pure gift
BUYOUT possible at this laughable low price potential buyers could be their partners like Endo or Mallinckrodt or other drug delivery companies
strong buy more good news on the way like the nda resubmission for their big drug oxycodone er
They had no cash thats why there was no progress in the company but now they have the money the need .
$1++ coming.. 5 more Drugs still awaiting FDA approval including Oxycodone ER their biggest drug for which NDA resubmission is on the way expected before year end . The next 6 months will be very interesting for this company .
Great Washout today now it can go up especially on NDA resubmission news for Oxycodone ER which could released any day now ..
RALLYYYYYYYYYYYYYYYYYY $1++ coming good news cominggg
Again im NOT a long term holder will dump within next 6-9 months likely before FDA decision and hopefully with a big profit . Im in with play money so i dont care IF i lose it .
$1++ coming especially with the NDA resubmission for Oxycodone ER which expected within 4 weeks ..STRONG BUY
$1++ coming soon
NDA resubmission for Oxycodone ER expected within 4-5 weeks this will attract a lot of new investors which will drive the sp much higher the closer we move to the FDA decision . TGT $3-4
more good news to come especially the NDA resubmission for Oxycodone ER which is expected before year end then the runup will start .
He did a great job on Biovail which later bought Valeant (now Bausch Health Companies) .
Looks like sellers are done now stock could likely run back above $1 in the coming days
Ok buddy i got it you dont like this stock but why you still waste your time with this stock why not looking for better investments ?
the downside risk is very limited because of their very low valuation of $12 million and cash balance around $12 million so there is nothing to worry at this time .If there is no news within next 3 months then maybe i consider selling .
my entry point was at around 0.53 and im happy with that
He got 4 Drugs through FDA approval and partner 2 of them with large Pharmas so he cant be bad as you tried to tell us
Stock is a strong buy at this price like it or not
But with wimusky raising an excellent point yesterday about how IPCI's proceeded with the Rexista oral and nasal HAP studies without doing phase III studies with the blue dye removed
In February 2018, the Company met with the FDA to discuss the above-referenced CRL for Oxycodone ER, including issues related to the blue dye in the product candidate. Based on those discussions, the product candidate will no longer include the blue dye. The blue dye was intended to act as an additional deterrent if Oxycodone ER is abused and serve as an early warning mechanism to flag potential misuse or abuse. The FDA confirmed that the removal of the blue dye is unlikely to have any impact on formulation quality and performance. As a result, the Company will not be required to repeat in vivo bioequivalence studies and pharmacokinetic studies submitted in the Oxycodone ER NDA. The FDA also indicated that, from an abuse liability perspective, Category 1 studies will not have to be repeated on Oxycodone ER with the blue dye removed.
The abuse liability studies for the intranasal route of abuse commenced in May 2018 with subject screening, while the studies to support abuse-deterrent label claims for the oral route of abuse commenced in June 2018. The clinical part of both studies has now been completed. Bioanalytical samples and statistical analysis for such studies are pending.
IPCI at this market cap of ridiculous $12 million is definitely the hottest Biotech with 6 Drugs awaiting FDA approval any news on that front will let this stock explode whatever the haters here says . It was a very risky gem last year indeed after FDA rejection and low cash balance but now they have the cash and NDA resubmission for that big Drug is around the corner . For new investors at this price its a very attractive gem and thats what counts .
YES he is the chief financial officer before his appointment in september 2017 the burn-rate was between $1.8m-2.5m a quarter since he takeover the cfo job the burn-rate doubled thats a fact .
Im happy that CFO steps down because during his time the burn-rate was relative high so i think even Odidi didnt like that .So i think the burn-rate is now going back down in the coming months and thats the good news .
better get some before she breakout above $1 and beyond
Buddy he cant resubmit in mid 2019 because FDA says they have time just until end of February .
The FDA granted our request for an extension to February 28, 2019 to resubmit our NDA for Oxycodone ER under section 505(b)(2) of the U.S. Federal Food, Drug and Cosmetic Act. However, we plan to resubmit the application later this year.
The future of this company depends on their game changer Oxycodone ER if it gets FDA approval in 1H 2019 then IPCI has best chance to turn profitable especially with a good partner on their side . I think Upfront payment for Oxycodone ER alone will be higher than the entire valuation of IPCI likey in the $15-25 Million range . But im here for the FDA runup and will likely dump a few days before FDA decision hopefully with a big profit .GLTA
The problem with Odidi is that he has to many jobs, he is Ceo ,Chairman and Cso of IPCI . Odidi is a great scientist and thats the only job he should do maybe he will step down as ceo .
Thank you buddy but i know how to handle such stocks its not the first time that i bought IPCI last time was in 2013 when stock jumped from around $2.50 to over $6 in just a few months . No i think its a great speculative play with the cash on hand ,very low valuation and the lots of near term milestones .Oh and im never invest to much money in such Biotechs .
The NDA Resubmission for their big drug Oxycodone ER expected before year end will attract a lot of new investors who wants to be in before FDA decision this will drive the sp to $3-4 easily .Thats why its a good entry point here at this low price .
MarketCap laughable $12 M / Cash balance $14 M / 6 Drugs awaiting FDA approval / NDA Resubmission for a BIG Pain Drug this Quarter FDA decision likely in 1H 2019 / RSI at 25 massive Oversold so at this time IPCI looks great on all fronts ..
Presentation October 2018
http://secfilings.nasdaq.com/filingFrameset.asp?FilingID=12999325&RcvdDate=10/5/2018&
RSI at 24 means still in the massive oversold area so it could run back above $1 even on no news just because of its very low valuation .
why not ? lots of biotechs did so
At this time we have 22 million shares outstanding
I dont see any risk after recent offering but huge upside if NDA resubmission for Oxycodone goes as planned before year end and any FDA approval for those 5 Drugs under review is a bonus .Market cap of $12 Million is definitely to cheap for this company so any good news will push the sp significantly higher and thats why im here .No risk no fun guys
Well lets see what happens in the coming weeks and months at this time they have enough cash for at least next 9-12 months and stock is trading close to ATL so i dont think its a mistake to buy some at this low price especially with a potential NDA resubmission befor year end and another 5 Drugs under review by FDA .
looks like youre short otherwise it would make no sense to waste your time here so better cover before your .... get burnt hehe .